PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.

PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is one of the best pure-play robotics stocks to buy now. PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is among the best pure-play robotics stocks to buy now. The ...

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

PROCEPT BioRobotics' Aquablation therapy has been upgraded to a strong recommendation in the updated European Association of Urology Guidelines as a preferred surgical treatment for benign prostatic ...

PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but ...

PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...

As of October 21, 2025, shares were priced at $34.61, down 48.57% year-over-year, and underperforming the S&P 500 by 63.63 percentage points. Procept BioRobotics is a healthcare technology company ...

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23, ...